229 related articles for article (PubMed ID: 38340237)
1. The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J; Shah M; Zakria D; Lockshin B; Crowley J; Merola JF; Gordon K; Shahriari M; Korman NJ; Chovatiya R; Kalb R; Lebwohl M
Dermatol Ther (Heidelb); 2024 Feb; 14(2):323-339. PubMed ID: 38340237
[TBL] [Abstract][Full Text] [Related]
2. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
J Drugs Dermatol; 2024 Feb; 23(2):54-60. PubMed ID: 38306124
[TBL] [Abstract][Full Text] [Related]
3. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
J Drugs Dermatol; 2023 Dec; 22(12):7691. PubMed ID: 38051842
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
10. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
14. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Armstrong A; Fahrbach K; Leonardi C; Augustin M; Neupane B; Kazmierska P; Betts M; Freitag A; Kiri S; Taieb V; Slim M; Gomez NN; Warren RB
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1777-1792. PubMed ID: 35798920
[TBL] [Abstract][Full Text] [Related]
19. Review of bimekizumab in the treatment of psoriasis.
Koppu S; Singh R; Kaur K; Feldman SR
Hum Vaccin Immunother; 2022 Nov; 18(6):2119767. PubMed ID: 36094828
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
